Eisai Co., Ltd. and its U.S. subsidiary Eisai Inc. (Headquarters: New Jersey, United States, Chairman & CEO: Hajime Shimizu) and its partner Helsinn Healthcare SA (Headquarters: Switzerland, CEO: Riccardo Braglia) announced the availability of ALOXI® (palonosetron hydrochloride) injection 0.075 mg for the prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. The introduction of ALOXI for PONV represents the first launch with an additional indication of an MGI PHARMA, INC. product since Eisai acquired the organization in January 2008.
The details can be read here
No comments:
Post a Comment